Simultaneous  ||| S:0 E:13 ||| JJ
oral  ||| S:13 E:18 ||| JJ
immunization  ||| S:18 E:31 ||| NN
of  ||| S:31 E:34 ||| IN
mice  ||| S:34 E:39 ||| NNS
with  ||| S:39 E:44 ||| IN
live  ||| S:44 E:49 ||| JJ
attenuated  ||| S:49 E:60 ||| FW
Escherichia  ||| S:60 E:72 ||| FW
coli  ||| S:72 E:77 ||| FW
expressing  ||| S:77 E:88 ||| FW
LT192-STa  ||| S:88 E:98 ||| NNP
13  ||| S:98 E:101 ||| CD
and  ||| S:101 E:105 ||| CC
LT  ||| S:105 E:108 ||| NNP
192-STb  ||| S:108 E:116 ||| NNP
fusion  ||| S:116 E:123 ||| NN
immunogen ||| S:123 E:132 ||| NN
,  ||| S:132 E:134 ||| ,
respectively ||| S:134 E:146 ||| RB
,  ||| S:146 E:148 ||| ,
for  ||| S:148 E:152 ||| IN
polyvalent  ||| S:152 E:163 ||| JJ
vaccine  ||| S:163 E:171 ||| NN
candidate  ||| S:171 E:181 ||| NN
Previous  ||| S:181 E:190 ||| JJ
epidemiological  ||| S:190 E:206 ||| JJ
study  ||| S:206 E:212 ||| NN
showed  ||| S:212 E:219 ||| VBD
that  ||| S:219 E:224 ||| IN
most  ||| S:224 E:229 ||| JJS
of  ||| S:229 E:232 ||| IN
the  ||| S:232 E:236 ||| DT
porcine  ||| S:236 E:244 ||| FW
enterotoxin  ||| S:244 E:256 ||| FW
Escherichia  ||| S:256 E:268 ||| FW
coli  ||| S:268 E:273 ||| FW
( ||| S:273 E:274 ||| -LRB-
ETEC ||| S:274 E:278 ||| NNP
)  ||| S:278 E:280 ||| -RRB-
strains  ||| S:280 E:288 ||| NNS
harbor  ||| S:288 E:295 ||| VBP
multiple  ||| S:295 E:304 ||| JJ
enterotoxins  ||| S:304 E:317 ||| NN
but  ||| S:317 E:321 ||| CC
lack  ||| S:321 E:326 ||| VBP
any  ||| S:326 E:330 ||| DT
of  ||| S:330 E:333 ||| IN
the  ||| S:333 E:337 ||| DT
fimbriae  ||| S:337 E:346 ||| NN
or  ||| S:346 E:349 ||| CC
non-fimbrial  ||| S:349 E:362 ||| JJ
adhesion  ||| S:362 E:371 ||| JJ
genes ||| S:371 E:376 ||| NNS
.  ||| S:376 E:378 ||| .
Therefore ||| S:378 E:387 ||| RB
,  ||| S:387 E:389 ||| ,
effective  ||| S:389 E:399 ||| JJ
ETEC  ||| S:399 E:404 ||| NN
vaccines  ||| S:404 E:413 ||| NNS
need  ||| S:413 E:418 ||| VBP
to  ||| S:418 E:421 ||| TO
aim  ||| S:421 E:425 ||| VB
directly  ||| S:425 E:434 ||| RB
at  ||| S:434 E:437 ||| IN
all  ||| S:437 E:441 ||| PDT
the  ||| S:441 E:445 ||| DT
enterotoxin  ||| S:445 E:457 ||| JJ
antigens ||| S:457 E:465 ||| NN
.  ||| S:465 E:467 ||| .
The  ||| S:467 E:471 ||| DT
objective  ||| S:471 E:481 ||| NN
of  ||| S:481 E:484 ||| IN
this  ||| S:484 E:489 ||| DT
study  ||| S:489 E:495 ||| NN
was  ||| S:495 E:499 ||| VBD
to  ||| S:499 E:502 ||| TO
evaluate  ||| S:502 E:511 ||| VB
the  ||| S:511 E:515 ||| DT
simultaneous  ||| S:515 E:528 ||| JJ
immune  ||| S:528 E:535 ||| JJ
effect  ||| S:535 E:542 ||| NN
of  ||| S:542 E:545 ||| IN
two  ||| S:545 E:549 ||| CD
live  ||| S:549 E:554 ||| JJ
attenuated  ||| S:554 E:565 ||| JJ
E.  ||| S:565 E:568 ||| NNP
coli  ||| S:568 E:573 ||| FW
strains  ||| S:573 E:581 ||| FW
expressing  ||| S:581 E:592 ||| FW
LTR192G-STaA13Q  ||| S:592 E:608 ||| FW
and  ||| S:608 E:612 ||| CC
LTR192G-STb  ||| S:612 E:624 ||| CD
fusion  ||| S:624 E:631 ||| NN
immunogen ||| S:631 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
respectively ||| S:642 E:654 ||| RB
.  ||| S:654 E:656 ||| .
The  ||| S:656 E:660 ||| DT
results  ||| S:660 E:668 ||| NNS
showed  ||| S:668 E:675 ||| VBD
that  ||| S:675 E:680 ||| IN
both  ||| S:680 E:685 ||| DT
local  ||| S:685 E:691 ||| JJ
mucosal  ||| S:691 E:699 ||| NN
and  ||| S:699 E:703 ||| CC
systemic  ||| S:703 E:712 ||| JJ
immune  ||| S:712 E:719 ||| JJ
responses  ||| S:719 E:729 ||| NNS
against  ||| S:729 E:737 ||| IN
LT ||| S:737 E:739 ||| NNP
,  ||| S:739 E:741 ||| ,
STa ||| S:741 E:744 ||| NNP
,  ||| S:744 E:746 ||| ,
STb ||| S:746 E:749 ||| NNP
,  ||| S:749 E:751 ||| ,
and  ||| S:751 E:755 ||| CC
F41  ||| S:755 E:759 ||| NNP
were  ||| S:759 E:764 ||| VBD
induced  ||| S:764 E:772 ||| VBN
in  ||| S:772 E:775 ||| IN
BALB ||| S:775 E:779 ||| NNP
/ ||| S:779 E:780 ||| NNP
c  ||| S:780 E:782 ||| SYM
mice  ||| S:782 E:787 ||| FW
immunized  ||| S:787 E:797 ||| FW
orally  ||| S:797 E:804 ||| FW
with  ||| S:804 E:809 ||| IN
the  ||| S:809 E:813 ||| DT
recombinant  ||| S:813 E:825 ||| JJ
E.  ||| S:825 E:828 ||| NNP
coli  ||| S:828 E:833 ||| NN
strains  ||| S:833 E:841 ||| NNS
ER-A  ||| S:841 E:846 ||| JJ
and  ||| S:846 E:850 ||| CC
ER-B  ||| S:850 E:855 ||| JJ
simultaneously ||| S:855 E:869 ||| NN
.  ||| S:869 E:871 ||| .
In  ||| S:871 E:874 ||| IN
addition ||| S:874 E:882 ||| NN
,  ||| S:882 E:884 ||| ,
results  ||| S:884 E:892 ||| NNS
of  ||| S:892 E:895 ||| IN
cellular  ||| S:895 E:904 ||| JJ
immune  ||| S:904 E:911 ||| JJ
responses  ||| S:911 E:921 ||| NNS
showed  ||| S:921 E:928 ||| VBD
that  ||| S:928 E:933 ||| DT
stimulation  ||| S:933 E:945 ||| JJ
index  ||| S:945 E:951 ||| NN
( ||| S:951 E:952 ||| -LRB-
SI ||| S:952 E:954 ||| NNP
)  ||| S:954 E:956 ||| -RRB-
values  ||| S:956 E:963 ||| NNS
of  ||| S:963 E:966 ||| IN
immunized  ||| S:966 E:976 ||| JJ
mice  ||| S:976 E:981 ||| NNS
were  ||| S:981 E:986 ||| VBD
significantly  ||| S:986 E:1000 ||| RB
higher  ||| S:1000 E:1007 ||| JJR
than  ||| S:1007 E:1012 ||| IN
control  ||| S:1012 E:1020 ||| NN
mice  ||| S:1020 E:1025 ||| NNS
( ||| S:1025 E:1026 ||| -LRB-
P    ||| S:1026 E:1028 ||| CD
< ||| S:1028 E:1029 ||| SYM
0.05 ||| S:1030 E:1034 ||| CD
)  ||| S:1034 E:1036 ||| -RRB-
and  ||| S:1036 E:1040 ||| CC
a  ||| S:1040 E:1042 ||| DT
marked  ||| S:1042 E:1049 ||| JJ
shift  ||| S:1049 E:1055 ||| NN
toward  ||| S:1055 E:1062 ||| IN
type-2  ||| S:1062 E:1069 ||| CD
helper  ||| S:1069 E:1076 ||| JJ
T  ||| S:1076 E:1078 ||| NN
lymphocyte  ||| S:1078 E:1089 ||| NNS
( ||| S:1089 E:1090 ||| -LRB-
Th  ||| S:1090 E:1093 ||| NNP
2 ||| S:1093 E:1094 ||| CD
)  ||| S:1094 E:1096 ||| -RRB-
immunity ||| S:1096 E:1104 ||| NN
.  ||| S:1104 E:1106 ||| .
Moreover ||| S:1106 E:1114 ||| RB
,  ||| S:1114 E:1116 ||| ,
the  ||| S:1116 E:1120 ||| DT
induced  ||| S:1120 E:1128 ||| JJ
antibodies  ||| S:1128 E:1139 ||| NNS
demonstrated  ||| S:1139 E:1152 ||| VBD
neutralizing  ||| S:1152 E:1165 ||| JJ
effects  ||| S:1165 E:1173 ||| NNS
on  ||| S:1173 E:1176 ||| IN
LT ||| S:1176 E:1178 ||| NNP
,  ||| S:1178 E:1180 ||| ,
STa ||| S:1180 E:1183 ||| NNP
,  ||| S:1183 E:1185 ||| ,
and  ||| S:1185 E:1189 ||| CC
STb  ||| S:1189 E:1193 ||| JJ
producing  ||| S:1193 E:1203 ||| VBG
E.  ||| S:1203 E:1206 ||| NNP
coli  ||| S:1206 E:1211 ||| JJ
infection ||| S:1211 E:1220 ||| NN
.  ||| S:1220 E:1222 ||| .
These  ||| S:1222 E:1228 ||| DT
data  ||| S:1228 E:1233 ||| NNS
indicated  ||| S:1233 E:1243 ||| VBD
that  ||| S:1243 E:1248 ||| IN
the  ||| S:1248 E:1252 ||| DT
use  ||| S:1252 E:1256 ||| NN
of  ||| S:1256 E:1259 ||| IN
recombinant  ||| S:1259 E:1271 ||| JJ
E.  ||| S:1271 E:1274 ||| NNP
coli  ||| S:1274 E:1279 ||| VBD
ER-A  ||| S:1279 E:1284 ||| JJ
and  ||| S:1284 E:1288 ||| CC
ER-B  ||| S:1288 E:1293 ||| NNP
could  ||| S:1293 E:1299 ||| MD
be  ||| S:1299 E:1302 ||| VB
a  ||| S:1302 E:1304 ||| DT
valuable  ||| S:1304 E:1313 ||| JJ
strategy  ||| S:1313 E:1322 ||| NN
for  ||| S:1322 E:1326 ||| IN
future  ||| S:1326 E:1333 ||| JJ
polyvalent  ||| S:1333 E:1344 ||| JJ
vaccine  ||| S:1344 E:1352 ||| NN
development  ||| S:1352 E:1364 ||| NN
of  ||| S:1364 E:1367 ||| IN
ETEC ||| S:1367 E:1371 ||| NNP
.  ||| S:1371 E:1373 ||| .
